UK Markets open in 1 hr 52 mins

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market to Reach $5.7 Billion by 2027

·10-min read

Abstract: - Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market to Reach $5. 7 Billion by 2027. - Amid the COVID-19 crisis, the global market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$5.

New York, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Industry" - https://www.reportlinker.com/p06032443/?utm_source=GNW
7 Billion by 2027, growing at aCAGR of 9.7% over the period 2020-2027. Medication, one of the segments analyzed in the report, is projected to record 7.7% CAGR and reach US$3.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Other Treatments segment is readjusted to a revised 14.8% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $881.8 Million, While China is Forecast to Grow at 9.2% CAGR
- The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market in the U.S. is estimated at US$881.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$994 Million by the year 2027 trailing a CAGR of 9.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.7% and 8.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

- Select Competitors (Total 40 Featured) -

  • Achillion Pharmaceuticals

  • Akari Therapeutics

  • Alexion Pharmaceuticals

  • Amgen Inc.

  • Apellis Pharmaceuticals

  • F. Hoffmann-La Roche AG.

  • GE Healthcare

  • Johnson & Johnson

  • Ra Pharmaceuticals

  • Regeneron Pharmaceuticals, Inc.

  • Takeda Pharmaceutical Company Limited (Shire Plc)

  • Thermo Fisher Scientific Inc.




Read the full report: https://www.reportlinker.com/p06032443/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Geographic Region -
Percentage Breakdown of Value Sales for USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets for Years
2012, 2020 & 2027

Table 4: World Current & Future Analysis for Medication by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 5: World Historic Review for Medication by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Medication by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Other Treatments
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 8: World Historic Review for Other Treatments by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Other Treatments by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 10: USA Current & Future Analysis for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Medication and Other Treatments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 11: USA Historic Review for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Medication and
Other Treatments Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 12: USA 15-Year Perspective for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Percentage
Breakdown of Value Sales for Medication and Other Treatments
for the Years 2012, 2020 & 2027

CANADA
Table 13: Canada Current & Future Analysis for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Medication and Other Treatments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 14: Canada Historic Review for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Medication and
Other Treatments Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 15: Canada 15-Year Perspective for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Percentage
Breakdown of Value Sales for Medication and Other Treatments
for the Years 2012, 2020 & 2027

JAPAN
Table 16: Japan Current & Future Analysis for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Medication and Other Treatments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 17: Japan Historic Review for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Medication and
Other Treatments Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 18: Japan 15-Year Perspective for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Percentage
Breakdown of Value Sales for Medication and Other Treatments
for the Years 2012, 2020 & 2027

CHINA
Table 19: China Current & Future Analysis for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Medication and Other Treatments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 20: China Historic Review for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Medication and
Other Treatments Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 21: China 15-Year Perspective for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Percentage
Breakdown of Value Sales for Medication and Other Treatments
for the Years 2012, 2020 & 2027

EUROPE
Table 22: Europe Current & Future Analysis for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: Europe Historic Review for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 24: Europe 15-Year Perspective for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Geographic Region -
Percentage Breakdown of Value Sales for France, Germany, Italy,
UK and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 25: Europe Current & Future Analysis for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Medication and Other Treatments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 26: Europe Historic Review for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Medication and
Other Treatments Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 27: Europe 15-Year Perspective for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Percentage
Breakdown of Value Sales for Medication and Other Treatments
for the Years 2012, 2020 & 2027

FRANCE
Table 28: France Current & Future Analysis for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Medication and Other Treatments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 29: France Historic Review for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Medication and
Other Treatments Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 30: France 15-Year Perspective for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Percentage
Breakdown of Value Sales for Medication and Other Treatments
for the Years 2012, 2020 & 2027

GERMANY
Table 31: Germany Current & Future Analysis for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Medication and Other Treatments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 32: Germany Historic Review for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Medication and
Other Treatments Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 33: Germany 15-Year Perspective for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Percentage
Breakdown of Value Sales for Medication and Other Treatments
for the Years 2012, 2020 & 2027

ITALY
Table 34: Italy Current & Future Analysis for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Medication and Other Treatments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 35: Italy Historic Review for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Medication and
Other Treatments Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 36: Italy 15-Year Perspective for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Percentage
Breakdown of Value Sales for Medication and Other Treatments
for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 37: UK Current & Future Analysis for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Medication and
Other Treatments - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 38: UK Historic Review for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Medication and
Other Treatments Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 39: UK 15-Year Perspective for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Percentage
Breakdown of Value Sales for Medication and Other Treatments
for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 40: Rest of Europe Current & Future Analysis for
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by
Treatment - Medication and Other Treatments - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 41: Rest of Europe Historic Review for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Medication and Other Treatments Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 42: Rest of Europe 15-Year Perspective for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Percentage Breakdown of Value Sales for Medication and Other
Treatments for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 43: Asia-Pacific Current & Future Analysis for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Medication and Other Treatments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 44: Asia-Pacific Historic Review for Paroxysmal Nocturnal
Hemoglobinuria (PNH) Treatment by Treatment - Medication and
Other Treatments Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 45: Asia-Pacific 15-Year Perspective for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Percentage Breakdown of Value Sales for Medication and Other
Treatments for the Years 2012, 2020 & 2027

REST OF WORLD
Table 46: Rest of World Current & Future Analysis for
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by
Treatment - Medication and Other Treatments - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 47: Rest of World Historic Review for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Medication and Other Treatments Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 48: Rest of World 15-Year Perspective for Paroxysmal
Nocturnal Hemoglobinuria (PNH) Treatment by Treatment -
Percentage Breakdown of Value Sales for Medication and Other
Treatments for the Years 2012, 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 40
Read the full report: https://www.reportlinker.com/p06032443/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting